The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-1126PMID 19351776
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2023cited by this paper
• Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2008cited by this paper
• Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence

  2008cited by this paper
• Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab.

  2006cited by this paper
• Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer

  2006cited by this paper
• Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Trastuzumab in metastatic breast cancer.

  2006cited by this paper
• Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.

  2005cited by this paper
• Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

  2005cited by this paper
• Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

  2004cited by this paper
• The immunobiology of cancer immunosurveillance and immunoediting.

  2004cited by this paper
• Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

  2004cited by this paper
• Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses

  2004cited by this paper
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• The clinical evaluation of HER‐2 status: which test to use?

  2003cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.

  2002cited by this paper
• Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

  2002cited by this paper
• Cardiac dysfunction in the trastuzumab clinical trials experience.

  2002cited by this paper
• Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

  2002cited by this paper
• Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.

  2000cited by this paper
• The HLA system. Second of two parts.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

  1999cited by this paper
• Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

  1998cited by this paper
• MHC Ligands and Peptide Motifs

  1998cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

  1994cited by this paper
• Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

  1992cited by this paper
• Distribution of HLA Antigens

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989influential reference
• Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987influential reference
• Measurement of Delayed Skin-Test Responses

  1975cited by this paper
• Editorial: Measurement of delayed skin-test responses.

  1975cited by this paper

• Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.

  2026cites this paper
• Advances in Immunotherapy for HER2 Low-Expressing Triple-Negative Breast Cancer

  2025cites this paper
• Recent update on multi-epitope vaccine development for treating breast cancer

  2025cites this paper
• Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review

  2023cites this paper
• Immunotherapies against HER2-Positive Breast Cancer

  2023cites this paper
• Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.

  2023cites this paper
• Potential association factors for developing effective peptide-based cancer vaccines

  2022cites this paper
• Immunological Landscape of HER-2 Positive Breast Cancer

  2022cites this paper
• Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives

  2022cites this paper
• Breast Cancer Vaccines: Disappointing or Promising?

  2022cites this paper
• Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine

  2022cites this paper
• A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells

  2022cites this paper
• Immunotherapy and immunobiomarker in breast cancer: current practice and future perspectives.

  2022cites this paper
• Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions

  2022cites this paper
• Immunotherapy as a partner for HER2-directed therapies

  2021cites this paper
• Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination

  2021cites this paper
• Breast cancer vaccines for treatment and prevention

  2021cites this paper
• Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer

  2021cites this paper
• Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

  2021cites this paper
• Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

  2021cites this paper
• The Exciting New Field of HER2-Low Breast Cancer Treatment

  2021cites this paper
• Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)

  2021cites this paper
• Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.

  2021cites this paper
• Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

  2020cites this paper
• Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

  2020cites this paper
• Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

  2020cites this paper
• The Whole View of Therapies for Breast Cancer

  2020cites this paper
• Clinical Data on Immunotherapy in Breast Cancer

  2020cites this paper
• BCTT_A_224758 69..75

  2020cites this paper
• Peptide vaccines in early breast cancer.

  2019cites this paper
• Breast cancer vaccines: Heeding the lessons of the past to guide a path forward.

  2019cites this paper
• Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

  2019cites this paper
• Cancer Vaccines Co-Targeting HER2/Neu and IGF1R

  2019cites this paper
• First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

  2019cites this paper
• Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

  2019cites this paper
• Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2019cites this paper
• Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.

  2019cites this paper
• Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

  2019cites this paper
• Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

  2019cites this paper
• Vaccine Therapies for Breast Cancer.

  2019cites this paper
• Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta‐analysis

  2018cites this paper
• Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here

  2018cites this paper
• HER2-Based Immunotherapy for Breast Cancer

  2018cites this paper
• Nano-biosensor for highly sensitive detection of HER2 positive breast cancer.

  2018cites this paper
• Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival

  2017influential citation
• [The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

  2017cites this paper
• Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

  2017cites this paper
• Novel Targeted Agents and Immunotherapy in Breast Cancer.

  2017cites this paper
• Frequency of Her2/Neu Protein Expression in Ovarian Epithelial Cancers.

  2017cites this paper
• The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives.

  2017cites this paper
• A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

  2017cites this paper
• A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice

  2017cites this paper
• Immunotherapy Approaches to Breast Cancer

  2017cites this paper
• La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques

  2017cites this paper
• Injecting Hope--A Review of Breast Cancer Vaccines.

  2016cites this paper
• Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.

  2016cites this paper
• Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.

  2016cites this paper
• The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.

  2016cites this paper
• Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

  2016cites this paper
• Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

  2016cites this paper
• Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

  2016cites this paper
• Immunotherapy for breast cancer: past, present, and future

  2016cites this paper
• Clinical Development of the E75 Vaccine in Breast Cancer

  2016cites this paper
• Breast Cancer Immunotherapy: Is It Ready for Prime Time?

  2015cites this paper
• Breast Cancer Immunotherapy.

  2015cites this paper
• Personalized Therapy of Cancer

  2015cites this paper
• Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration

  2015cites this paper
• Breast Cancer Vaccines: Injecting Hope

  2015cites this paper
• Immune targeting in breast cancer.

  2015cites this paper
• CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers

  2015influential citation
• HER2-directed therapy: current treatment options for HER2-positive breast cancer

  2015cites this paper
• Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

  2015cites this paper
• Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients

  2015cites this paper
• HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy

  2015cites this paper
• Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer

  2014cites this paper
• The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

  2014cites this paper
• Personalized Cancer Therapy

  2014cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• Two dimensions in targeting HER2.

  2014cites this paper
• Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

  2014cites this paper
• Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.

  2014cites this paper
• Ex vivo imaging immune cell interactions in T cell vaccine-induced immunity and CD8+CD25+ T regulatory cell-mediated immune suppression

  2013cites this paper
• The two sides of HER2/neu: immune escape versus surveillance.

  2013cites this paper
• Rethinking cancer vaccines to avoid T-cell traps.

  2013cites this paper
• "While we can avoid the T-cell trap of incomplete Freund's adjuvant by the use of short-lived adjuvants, the only avoidance of the potential for a tumor T-cell trap is to vaccinate cancer patients earlier in their disease course. "

  2013cites this paper
• Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

  2013cites this paper
• Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

  2013cites this paper
• Monoclonal antibodies therapies for ovarian cancer

  2013cites this paper
• Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

  2013cites this paper
• New developments and concepts related to biomarker application to vaccines

  2012cites this paper
• Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression

  2012influential citation
• Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles.

  2012cites this paper
• Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from Phase/I and II clinical trials

  2012cites this paper
• Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients

  2012cites this paper
• Opposing consequences of signaling through EGF family members

  2012cites this paper
• Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

  2012cites this paper
• Immunoproteomics of HER2-Positive and HER2-Negative Breast Cancer Patients with Positive Lymph Nodes

  2011cites this paper
• Camouflage and sabotage: tumor escape from the immune system

  2011cites this paper
• OT3-01-18: Combination Immunotherapy with Trastuzumab and the HER2 Vaccine E75 in Low and Intermediate HER2−Expressing Breast Cancer Patients To Prevent Recurrence.

  2011cites this paper
• Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.

  2011cites this paper